Molecular targeting of malignant glioma cells with an EphA2-specific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells

Cancer Letters

Volumn 312, Issue 2, 2011, Pages 168-177

  Sun, Xin lin ^a,b   Xu, Zhi min ^a,b,c   Ke, Yi quan ^a,b   Hu, Chang chen ^d   Wang, Shi yong ^a,b   Ling, Geng qiang ^a,b   Yan, Zhong jie ^a,b,c   Liu, Yi jing ^a,b   Song, Zhen hua ^a,b   Jiang, Xiao dan ^a,b   Xu, Ru xiang ^b,c  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

Author keywords

EphA2; Gene therapy; Immunotoxin; Malignant glioma; Mesenchymal stem cells

Indexed keywords

ADENOVIRUS VECTOR; EPHRIN A1; EPHRIN A1 PSEUDOMONAS EXOTOXIN 38; EPHRIN RECEPTOR A2; IMMUNOTOXIN; PSEUDOMONAS EXOTOXIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW; CANCER INHIBITION; CELL KILLING; CELL PROLIFERATION; CELL SECRETION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MESENCHYMAL STEM CELL; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL GENE THERAPY; TARGET CELL; TOXIN SYNTHESIS; TUMOR MODEL; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; BONE MARROW CELLS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DNA PRIMERS; FEMALE; GLIOMA; HUMANS; IMMUNOTOXINS; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED BALB C; POLYMERASE CHAIN REACTION; RECEPTOR, EPHA2;

ADENOVIRIDAE;

EID: 80053976962     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.07.035     Document Type: Article

References (43)

1. Y. Nakazato, The fourth Ed. of WHO Classification of Tumours of the Central Nervous System published in 2007. No Shinkei Geka 36 (2008) 473-491.
2. Pastan I., Hassan R., FitzGerald D.J., Kreitman R.J. Immunotoxin treatment of cancer. Annual Review of Medicine 2007, 58:221-237.
3. Kreitman R.J. Immunotoxins for targeted cancer therapy. The AAPS Journal 2006, 8:E532-551.
4. Rustamzadeh E., Low W.C., Vallera D.A., Hall W.A. Immunotoxin therapy for CNS tumor. Journal of Neuro-Oncology 2003, 64:101-116.
5. Hall B., Dembinski J., Sasser A.K., Studeny M., Andreeff M., Marini F. Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles. International Journal of Hematology 2007, 86:8-16.
6. Ozawa K., Sato K., Oh I., Ozaki K., Uchibori R., Obara Y., Kikuchi Y., Ito T., Okada T., Urabe M., Mizukami H., Kume A. Cell and gene therapy using mesenchymal stem cells (MSCs). Journal of Autoimmunity 2008, 30:121-127.
7. Debinski W. Molecular targeting with recombinant cytotoxins for the treatment of brain tumors. Drug Development Research 2008, 69:407-414.
8. Nakamizo A., Marini F., Amano T., Khan A., Studeny M., Gumin J., Chen J., Hentschel S., Vecil G., Dembinski J., Andreeff M., Lang F.F. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Research 2005, 65:3307-3318.
9. Lee D.H., Ahn Y., Kim S.U., Wang K.C., Cho B.K., Phi J.H., Park I.H., Black P.M., Carroll R.S., Lee J., Kim S.K. Targeting rat brainstem glioma using human neural stem cells and human mesenchymal stem cells. Clinical Cancer Research 2009, 15:4925-4934.
10. Nakamura K., Ito Y., Kawano Y., Kurozumi K., Kobune M., Tsuda H., Bizen A., Honmou O., Niitsu Y., Hamada H. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Therapy 2004, 11:1155-1164.
11. Wykosky J., Gibo D.M., Stanton C., Debinski W. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Molecular Cancer Research 2005, 3:541-551.
12. Hatano M., Eguchi J., Tatsumi T., Kuwashima N., Dusak J.E., Kinch M.S., Pollack I.F., Hamilton R.L., Storkus W.J., Okada H. EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia 2005, 7:717-722.
13. Surawska H., Ma P.C., Salgia R. The role of ephrins and Eph receptors in cancer. Cytokine & Growth Factor Reviews 2004, 15:419-433.
14. Noblitt L.W., Bangari D.S., Shukla S., Mohammed S., Mittal S.K. Immunocompetent mouse model of breast cancer for preclinical testing of EphA2-targeted therapy. Cancer Gene Therapy 2005, 12:46-53.
15. Walker-Daniels J., Coffman K., Azimi M., Rhim J.S., Bostwick D.G., Snyder P., Kerns B.J., Waters D.J., Kinch M.S. Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 1999, 41:275-280.
16. Margaryan N.V., Strizzi L., Abbott D.E., Seftor E.A., Rao M.S., Hendrix M.J., Hess A.R. EphA2 as a promoter of melanoma tumorigenicity. Cancer Biology & Therapy 2009, 8:279-288.
17. Lu C., Shahzad M.M., Wang H., Landen C.N., Kim S.W., Allen J., Nick A.M., Jennings N., Kinch M.S., Bar-Eli M., Sood A.K. EphA2 overexpression promotes ovarian cancer growth. Cancer Biology & Therapy 2008, 7:1098-1103.
18. Ogawa K., Pasqualini R., Lindberg R.A., Kain R., Freeman A.L., Pasquale E.B. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 2000, 19:6043-6052.
19. Hess A.R., Seftor E.A., Gardner L.M., Carles-Kinch K., Schneider G.B., Seftor R.E., Kinch M.S., Hendrix M.J. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Research 2001, 61:3250-3255.
20. Wykosky J., Palma E., Gibo D.M., Ringler S., Turner C.P., Debinski W. Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor. Oncogene 2008, 27:7260-7273.
21. Hu C.C., Ke Y.Q., Sun X.L., Jiang X.D., Xu R.X., Lv J., Wang Y.S., Cai Y.Q., Qin L.S., Zou Y.X. Human mesenchymal stem cells-like cells as cellular vehicles for delivery of immunotoxin in vitro. Biotechnology Letters 2009, 31:181-189.
22. Gale N.W., Holland S.J., Valenzuela D.M., Flenniken A., Pan L., Ryan T.E., Henkemeyer M., Strebhardt K., Hirai H., Wilkinson D.G., Pawson T., Davis S., Yancopoulos G.D. Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron 1996, 17:9-19.
23. Bruce V., Olivieri G., Eickelberg O., Miescher G.C. Functional activation of EphA5 receptor does not promote cell proliferation in the aberrant EphA5 expressing human glioblastoma U-118 MG cell line. Brain Research 1999, 821:169-176.
24. Zovickian J., Johnson V.G., Youle R.J. Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin. Journal of Neurosurgery 1987, 66:850-861.
25. Hall W.A., Fodstad O. Immunotoxins and central nervous system neoplasia. Journal of Neurosurgery 1992, 76:1-12.
26. Puri S., Puri S., Mahapatra A.K., Hussain E., Sarkar C., Sinha S., Joshi B.H. A review of studies on targeting interleukin 4 receptor for central nervous system malignancy. Current Molecular Medicine 2009, 9:732-739.
27. Mintz A., Gibo D.M., Madhankumar A.B., Debinski W. Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma. Journal of Neuro-Oncology 2003, 64:117-123.
28. Liu T.F., Hall P.D., Cohen K.A., Willingham M.C., Cai J., Thorburn A., Frankel A.E. Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice. Clinical Cancer Research 2005, 11:329-334.
29. Hammond S.A., Lutterbuese R., Roff S., Lutterbuese P., Schlereth B., Bruckheimer E., Kinch M.S., Coats S., Baeuerle P.A., Kufer P., Kiener P.A. Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct. Cancer Research 2007, 67:3927-3935.
30. Wykosky J., Gibo D.M., Debinski W. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells. Molecular Cancer Therapeutics 2007, 6:3208-3218.
31. Jin N., Chen W., Blazar B.R., Ramakrishnan S., Vallera D.A. Gene therapy of murine solid tumors with T cells transduced with a retroviral vascular endothelial growth factor-immunotoxin target gene. Human Gene Therapy 2002, 13:497-508.
32. Vallera D.A., Jin N., Baldrica J.M., Panoskaltsis-Mortari A., Chen S.Y., Blazar B.R. Retroviral immunotoxin gene therapy of acute myelogenous leukemia in mice using cytotoxic T cells transduced with an interleukin 4/diphtheria toxin gene. Cancer Research 2000, 60:976-984.
33. Stocker M., Tur M.K., Sasse S., Krussmann A., Barth S., Engert A. Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of transfected 293T-cells. Protein Expression and Purification 2003, 28:211-219.
34. Chen S.Y., Yang A.G., Chen J.D., Kute T., King C.R., Collier J., Cong Y., Yao C., Huang X.F. Potent antitumour activity of a new class of tumour-specific killer cells. Nature 1997, 385:78-80.
35. Jia J., Li H., Tai S., Lv M., Liao M., Yang Z., Zhang B., Zhou B., Zhang G., Zhang L. Construction and preliminary investigation of a plasmid containing a novel immunotoxin DT390-IL-18 gene for the prevention of murine experimental autoimmune encephalomyelitis. DNA and Cell Biology 2008, 27:279-285.
36. Rustamzadeh E., Vallera D.A., Todhunter D.A., Low W.C., Panoskaltsis-Mortari A., Hall W.A. Immunotoxin pharmacokinetics: a comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13. Journal of Neuro-Oncology 2006, 77:257-266.
37. Potala S., Sahoo S.K., Verma R.S. Targeted therapy of cancer using diphtheria toxin-derived immunotoxins. Drug Discovery Today 2008, 13:807-815.
38. Debinski W., Tatter S.B. Convection-enhanced delivery for the treatment of brain tumors. Expert Review of Neurotherapeutics 2009, 9:1519-1527.
39. Bidros D.S., Liu J.K., Vogelbaum M.A. Future of convection-enhanced delivery in the treatment of brain tumors. Future Oncology 2010, 6:117-125.
40. Hall W.A. Convection-enhanced delivery: neurosurgical issues. Current Drug Targets 2009, 10:126-130.
41. Mohr A., Lyons M., Deedigan L., Harte T., Shaw G., Howard L., Barry F., O'Brien T., Zwacka R. Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model. Journal of Cellular and Molecular Medicine 2008, 12:2628-2643.
42. Chirmule N., Propert K., Magosin S., Qian Y., Qian R., Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Therapy 1999, 6:1574-1583.
43. Stish B.J., Chen H., Shu Y., Panoskaltsis-Mortari A., Vallera D.A. A bispecific recombinant cytotoxin (DTEGF13) targeting human interleukin-13 and epidermal growth factor receptors in a mouse xenograft model of prostate cancer. Clinical Cancer Research 2007, 13:6486-6493.